Overview

A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia

Status:
Completed

Trial end date:
2011-08-01

Target enrollment:

Participant gender:

Summary

An open-label phase 1 study to assess safety and efficacy of once-weekly STA-9090 (ganetespib) in subjects with AML, ALL and blast-phase CML.

Phase:

Phase 1

Details

Lead Sponsor:

Synta Pharmaceuticals Corp.